As of Jan 20
| -0.05 / -0.21%|
The 6 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 30.00, with a high estimate of 37.00 and a low estimate of 22.00. The median estimate represents a +27.93% increase from the last price of 23.45.
The current consensus among 6 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.